---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018636"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T22:42:56.844024+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma regains Nasdaq compliance with $2.5M equity rule; under monitoring until Feb 2026

## Summary
- Received Nasdaq confirmation on Feb 25, 2025 of compliance with minimum $2.5M stockholders' equity requirement.
- Subject to mandatory panel monitoring through Feb 25, 2026; future non-compliance may lead to delisting without cure period.
- Closed $20M gross proceeds offering on Dec 30, 2024 to strengthen financial position.
- CEO cites potential transformational year ahead with bird flu/influenza antiviral pipeline.

## SEC filing metadata
- accession: 0001104659-25-018636
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/0001104659-25-018636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/tm257866d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018636
- JSON: https://secwatch.observer/filing/0001104659-25-018636.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.